{
    "title": "Developing novel ligands with enhanced binding affinity for the sphingosine 1-phosphate receptor 1 using machine learning. (arXiv:2307.16037v1 [cs.LG])",
    "abstract": "Multiple sclerosis (MS) is a debilitating neurological disease affecting nearly one million people in the United States. Sphingosine-1-phosphate receptor 1, or S1PR1, is a protein target for MS. Siponimod, a ligand of S1PR1, was approved by the FDA in 2019 for MS treatment, but there is a demonstrated need for better therapies. To this end, we finetuned an autoencoder machine learning model that converts chemical formulas into mathematical vectors and generated over 500 molecular variants based on siponimod, out of which 25 compounds had higher predicted binding affinity to S1PR1. The model was able to generate these ligands in just under one hour. Filtering these compounds led to the discovery of six promising candidates with good drug-like properties and ease of synthesis. Furthermore, by analyzing the binding interactions for these ligands, we uncovered several chemical properties that contribute to high binding affinity to S1PR1. This study demonstrates that machine learning can ac",
    "link": "http://arxiv.org/abs/2307.16037",
    "context": "Title: Developing novel ligands with enhanced binding affinity for the sphingosine 1-phosphate receptor 1 using machine learning. (arXiv:2307.16037v1 [cs.LG])\nAbstract: Multiple sclerosis (MS) is a debilitating neurological disease affecting nearly one million people in the United States. Sphingosine-1-phosphate receptor 1, or S1PR1, is a protein target for MS. Siponimod, a ligand of S1PR1, was approved by the FDA in 2019 for MS treatment, but there is a demonstrated need for better therapies. To this end, we finetuned an autoencoder machine learning model that converts chemical formulas into mathematical vectors and generated over 500 molecular variants based on siponimod, out of which 25 compounds had higher predicted binding affinity to S1PR1. The model was able to generate these ligands in just under one hour. Filtering these compounds led to the discovery of six promising candidates with good drug-like properties and ease of synthesis. Furthermore, by analyzing the binding interactions for these ligands, we uncovered several chemical properties that contribute to high binding affinity to S1PR1. This study demonstrates that machine learning can ac",
    "path": "papers/23/07/2307.16037.json",
    "total_tokens": 1063,
    "translated_title": "利用机器学习开发具有增强结合亲和力的新型配体对于S1PR1",
    "translated_abstract": "多发性硬化症（MS）是一种影响美国近一百万人的严重神经系统疾病。Sphingosine-1-phosphate receptor 1（S1PR1）是MS的一个蛋白靶点。Siponimod，S1PR1的一个配体，于2019年被FDA批准用于MS治疗，但仍然需要更好的疗法。为此，我们通过优化一个自编码器机器学习模型，将化学公式转化为数学向量，并生成了500多个基于siponimod的分子变体，其中25个化合物对S1PR1的预测结合亲和力更高。该模型能够在不到一小时的时间内生成这些配体。对这些化合物进行筛选，发现了六个具有良好药物样性和易于合成的有前景的候选物。此外，通过分析这些配体的结合相互作用，我们发现了几个有助于高结合亲和力的化学性质。该研究表明，机器学习可以加速药物研发过程，并发现具有增强结合亲和力的新型配体。",
    "tldr": "该研究利用机器学习开发了具有增强结合亲和力的新型配体对于多发性硬化症（MS）治疗。研究通过对基于siponimod的分子变体进行大规模生成和筛选，发现了六个有前景的具有良好药物样性和易于合成的候选物，并通过分析发现了几个有助于高结合亲和力的化学性质。",
    "en_tdlr": "This study developed novel ligands with enhanced binding affinity for multiple sclerosis (MS) treatment using machine learning. By generating and filtering molecular variants based on siponimod, six promising candidates with good drug-like properties and ease of synthesis were discovered. Analysis of binding interactions also revealed key chemical properties contributing to high binding affinity."
}